NYSDA Publications

FDA Issues New Safety Label Warnings for Benzodiazepines

The United States Food and Drug Administration (FDA) has issued new labeling requirements for benzodiazepines to include warnings of the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions to help improve their safe use.  To read the FDA announcement and summary of its required labeling changes for benzodiazepines, use the first link below.  To read the FDA benzodiazepine safety warning to health care professionals and the public, use the second link below.
https://www.fda.gov/news-events/press-announcements/fda-requiring-labeling-changes-benzodiazepines?utm_medium=email&utm_source=govdelivery  (FDA announcement and summary of its required labeling changes for benzodiazepines)
https://www.fda.gov/safety/medical-product-safety-information/benzodiazepine-drug-class-drug-safety-communication-boxed-warning-updated-improve-safe-use?utm_medium=email&utm_source=govdelivery  (FDA benzodiazepine safety warning to health care professionals and public)
"Local":"NewYorkCountyNY"